2017
DOI: 10.1002/term.2394
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Many clinical studies of regenerative medicine using bone marrow-derived mesenchymal stem cells (MSCs) have been conducted globally. We initiated clinical studies using MSCs in 2001 and have now treated over 100 cases with patients aged 0-92 years. In a few cases involving patients with chronic heart failure (CHF), we observed that MSCs proliferated poorly. This contrasts with cell therapy studies wherein MSCs of patients with CHF were used for treatment. The effects of serum on the proliferation of MSCs from … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(7 citation statements)
references
References 21 publications
0
7
0
Order By: Relevance
“…Overall, our data confirm that the proliferation profiles of CB-MSCs are significantly better under the cultivation with human serum, regardless of whether the donor suffered from CHF or not. Kubo et al recently reported that autologous serum from older donors with CHF prolonged the population doubling times of BM-MSCs, as compared to FBS and serum from donors without CHF [ 22 ]. “Aged” serum was also found to negatively affect mesenchymal stem cells in mice [ 31 ], and aging satellite cells could be rejuvenated when exposed to a young serum [ 32 , 33 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Overall, our data confirm that the proliferation profiles of CB-MSCs are significantly better under the cultivation with human serum, regardless of whether the donor suffered from CHF or not. Kubo et al recently reported that autologous serum from older donors with CHF prolonged the population doubling times of BM-MSCs, as compared to FBS and serum from donors without CHF [ 22 ]. “Aged” serum was also found to negatively affect mesenchymal stem cells in mice [ 31 ], and aging satellite cells could be rejuvenated when exposed to a young serum [ 32 , 33 ].…”
Section: Resultsmentioning
confidence: 99%
“…Other groups, including our team, have previously shown that serum from patients with heart failure can impair MSC function [ 21 ]. In fact, a retrospective analysis of patients with chronic heart failure (CHF) treated with BM-MSCs that were cultured in either FBS or autologous serum demonstrated less variance in population doublings in the FBS group [ 22 ].…”
Section: Introductionmentioning
confidence: 99%
“…In clinical situations, the use of passage 0 synovial MSCs could be valuable in reducing the effort required by replating as well as in preventing the possible risks related to chromosomal abnormalities [11,12]. This result is important for other MSCs derived from bone marrow [13,14], adipose tissues [15], and other mesenchymal tissues when the MSCs are cultured with human serum.…”
Section: Discussionmentioning
confidence: 99%
“…11 Numerous studies have confirmed that aging and risk factors of the heart disease could reduce the treatment capacity of the stem cells. 12 So, allogeneic stem cells collected from young and healthy candidates might have more beneficial effects than autologous cells gathered from old patients diagnosed with heart disease. 13 The isolation of MSCs according to the International Society for Cellular Therapy (ISCT) criteria creates heterogeneous, nonclonal cultures of stromal cells comprising stem cells with diverse multipotential properties, committed progenitors, and differentiated cells.…”
Section: Introductionmentioning
confidence: 99%